Wright will pay another $190 million if BioMimetic’s Augment Bone Graft technology receives FDA approval, and a decision is expected to be made between April 2013 and January 2014.
Wright Medical Group develops and manufactures orthopedic devices and will incorporate BioMimetic’s biologics offerings.
More Articles on Devices:
Invibio to Attend 2013 AAOS Annual Meeting
OsteoMed Launches QWIK Bone Fill Material
TranS1 Posts $12M 4Q Loss
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
